Home

Lineage Cell Therapeutics, Inc.

CIK 876343 · last filed 2020-01-06

Lineage Cell Therapeutics, Inc. is a corporate insider who has filed 5 SEC Form 4 insider transactions across 2 companies since 2016. The most recent filing shows the insider sold $5.1M of OCX on Jan 6, 2020. Across all open-market trades the lifetime net is −$16.3M, making them a net seller over the disclosed history. The firm reports its address in Carlsbad, CA. 98 SEC filings were submitted jointly with ALFRED D KINGSLEY.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

2

Total Filings

5

Lifetime Open-Market Net

-$16.28M

Filer Profile

Reported Address
2173 SALK AVENUE
SUITE 200
CARLSBAD, CA 92008
Phone
(510) 521-3390
State of Incorporation
CA
Formerly Known As
BIOTIME INC (1996–2019)
Related Filers
ALFRED D KINGSLEY — 98 joint filings, latest 2023-07-03
BROADWOOD PARTNERS, L.P. — 73 joint filings, latest 2025-11-14
Neal C Bradsher — 59 joint filings, latest 2026-07-02
BROADWOOD CAPITAL INC — 43 joint filings, latest 2025-01-28
Brian M Culley — 34 joint filings, latest 2026-03-12
GREENBELT CORP /NY — 34 joint filings, latest 2020-02-14
MICHAEL D WEST — 33 joint filings, latest 2018-09-19
JUDITH SEGALL — 32 joint filings, latest 2017-02-14
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
Insight Molecular Diagnostics Inc. (OCX) Delisted 10%+ Owner 302,058 $3.20 $966.6K -$16.28M 3 2020-01-06
Asterias Biotherapeutics, Inc. (AST) Delisted 10%+ Owner 21,747,569 — — $0 1 2016-03-02

Recent Filings

5 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2020-01-06 Insight Molecular Diagnostics Inc. (OCX) Delisted Sell (S) −2,383,090 -$5.14M EDGAR
2019-09-13 Insight Molecular Diagnostics Inc. (OCX) Delisted Sell (S) −4,000,000 -$6.64M EDGAR
2019-07-05 Insight Molecular Diagnostics Inc. (OCX) Delisted Sell (S) −2,250,000 -$4.50M EDGAR
2016-03-02 Asterias Biotherapeutics, Inc. (AST) Delisted Other (J) −75,771 $0 EDGAR
2013-10-02 — Other (J) +21,773,340 $50.97M
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.